May 2026 Sartorius Stedim Biotech continued expanding its single-use bioprocessing capabilities through investments in cell and gene therapy manufacturing solutions. The company highlighted integrated technologies supporting upstream and downstream bioprocess workflows, including processes requiring efficient cell handling, disruption, and sample preparation.
February 2026 Nucleus Biologics launched Krakatoa® K500, a pod-based, on-demand media and buffer manufacturing system designed for advanced cell therapy and bioproduction workflows. The company stated that the closed, single-use platform supports automated preparation of sterile media and buffers, helping improve scalability and efficiency in cell-based manufacturing processes.
2025 Thermo Fisher Scientific continued advancing its cell disruption and sample preparation portfolio, including laboratory instruments, reagents, and consumables used for protein extraction, nucleic acid isolation, and bioprocessing workflows. The company continued supporting pharmaceutical, biotechnology, and research laboratories with automated and scalable solutions.
2025 Danaher Corporation (Beckman Coulter Life Sciences) continued developing advanced laboratory automation and sample preparation technologies supporting cell biology research and bioprocessing applications. The company continued integrating automation and precision technologies for workflows involving cell processing and biomolecule analysis.